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Introduction
Ocular infections are caused by a wide variety of infectious 
agents and present in many different guises. The causative 
agents may broadly be divided into the same four groups 
of organisms that cause infection elsewhere in the body: 
viral, bacterial, fungal and parasitic. All of these groups are 
capable of infecting the superficial layers of the eye, such 
as the conjunctiva and the cornea, as well as deeper ocular 
structures, such as the vitreous humour and the retina. The 
route of administration of the appropriate anti-infective 
preparation is largely determined by the site of the primary 
infection. Therefore, cases of infectious conjunctivitis and 
keratitis are primarily treated with topical preparations, 
whereas intraocular infections, such as endophthalmitis or 
retinitis, usually require periocular, intraocular or systemic 
administration of anti-infective preparations. 
Classification of anti-infective 
ophthalmic preparations
Preparations are available to treat eye infections that are 
caused by organisms in all four abovementioned groups. 
Table I provides an outline of the different drug classes, 
as well as the specific available drugs in each class. A 
fifth class is also included. This contains preparations that 
are effective against more than one class of infectious 
organisms.
Antibacterial ophthalmic preparations
Sulphacetamide
Available preparation: 10% ointment
Sulphacetamide is a bacteriostatic sulphonamide with 
limited ophthalmic use. It may be combined with oral 
erythromycin, azithromycin or clarithromycin for the 
treatment of chlamydial conjunctivitis, and should then 
be used two or three times a day for 3-6 weeks.1 It should 
not be used by patients with a known hypersensitivity to 
sulphonamide drugs.2 
Propamidine isethionate
Available preparation: 1mg/ml drops
Propamidine isethionate may be used for treating mild 
bacterial conjunctivitis caused by staphylococci and 
streptococci, but is not effective against Pseudomonas spp. 
or Escherichia coli. If a superficial eye infection does not 
improve within one week of treatment, a change in therapy 
to a drug with a broader spectrum should be considered. 
Propamidine isethionate also plays an important role in 
the treatment of Acanthamoeba keratitis, which needs to 
be excluded in contact lens wearers who present with a 
corneal infection that initially mimics herpetic keratitis, but 
does not respond to the usual treatment for that condition.
Fusidic acid
Available preparation: 10 mg/g viscous drops
Generally, fusidic acid is considered to have a narrow spec-
trum of activity which predominantly covers staphylococcal 
infections such as blepharitis or conjunctivitis. However, in a 
Canadian study that compared the topical use of 1% fusidic 
acid to 0.3% tobramycin to treat acute bacterial conjuncti-
vitis, no difference in efficacy was demonstrated between 
the two drugs. The twice-daily dosage regimen was also 
found to be more convenient than the frequent installations 
required for tobramycin drops.3
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Silver nitrate
The story of Dr Carl Credé and the prevention of ophthalmia 
neonatorum with silver nitrate drops is well worth reading, 
and may be accessed free of charge at the following 
web address: http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC1721147/pdf/v083p0F158.pdf
Very few interventions have had such a profound impact on 
a medical condition worldwide.4 Credé originally advocated 
the use of a 2% silver nitrate solution, but this concentration 
was later halved. Today, silver nitrate is no longer widely 
used, although it should still be considered in cases in which 
Neisseria gonorrhoeae infection is prevalent. However, it 
does not provide adequate protection against Chlamydia 
trachomatis infection. This, combined with the occurrence 
of a mild chemical conjunctivitis in neonates, is the main 
reason why its use has been discontinued.
Chloramphenicol
Available preparations: 0.5% preserved drops, 1% ointment 
and 0.5% preservative-free, single-dose units
Chloramphenicol is the most frequently used broad-
spectrum topical antibiotic in South Africa and is effective in 
more than 99% of superficial bacterial eye infections.2 It is 
clinically effective against the majority of Gram-positive and 
Gram-negative organisms. Therefore, it still plays an integral 
role in the first-line treatment of bacterial conjunctivitis and 
blepharitis. 
The ocular toxicity of topical chloramphenicol is low, 
although it may serve as a trigger for delayed allergic 
contact dermatitis or conjunctivitis. Aplastic anaemia and 
other blood dyscrasias have been linked to the ocular use of 
chloramphenicol, although it has been shown that the risk 
is less than one per million treatment courses. Therefore, 
use of this drug to treat superficial eye infections should 
not be precluded.5 In South Africa, it is also recommended 
for the prevention of neonatal conjunctivitis.2 Interestingly 
enough, the only drug that has been approved by the United 
States Food and Drug Administration for the prevention of 
neonatal conjunctivitis is erythromycin 0.5% ophthalmic 
ointment. This is not available in South Africa.6
Tobramycin
Available preparations: 3 mg/ml drops and 3 mg/g ointment
Since gentamycin eye drops were discontinued a few years 
ago, tobramycin is now the only commercially available 
topical aminoglycoside preparation in South Africa. It is 
active against most Gram-negative bacteria, as well as a few 
aerobic Gram-positive microbes, especially staphylococci. 
It has been a reliable treatment option for superficial eye 
infections for many years, and was previously often used 
as the gold standard in clinical trials in which newer 
preparations needed to be compared to a well-established 
drug.
It may cause transient stinging after installation and 
hypersensitivity reactions have been reported, but these are 
rare.
Ciprofloxacin
Available preparations: 3 mg/ml drops and 3 mg/g ointment
Ciprofloxacin, a class II second-generation fluoroquinolone, 
has a broad spectrum of activity against both Gram-
positive and Gram-negative bacteria, although it is often 
not effective against Streptococcus pneumoniae. However, 
it does have more activity against Pseudomonas aeruginosa 
than any other fluoroquinolone that is currently available.7 
It is effective is most cases of bacterial conjunctivitis and 
will also successfully treat the majority of small peripheral 
corneal ulcers. Oral administration of ciprofloxacin results 
in high intraocular levels of the drug. Therefore, it is 
recommended as prophylaxis for traumatic endophthalmitis 
in all open-eye injuries. This includes paediatric cases since 
the benefit is considered to outweigh the risk of damage to 
cartilage in weight-bearing joints. The recommended dose 
in adults is 750 mg twice daily, and in children, 5-10 mg/kg/
dose twice daily, and up to a maximum of 500 mg per dose.2
Ofloxacin
Available preparations: 3 mg/ml drops and 3 mg/g ointment
Ofloxacin is another class II second-generation fluoroqui-
nolone. Therefore, it has a similar spectrum of activity and 
application to ciprofloxacin, although it is not as effective 
against P. aeruginosa.
Gatifloxacin
Available preparation: 3 mg/ml drops
Gatifloxacin is a third-generation fluoroquinolone with 
a Gram-negative spectrum that is similar to that of the 
second-generation drugs, but with improved Gram-positive 
coverage. It is two to four times more active against 
S. pneumoniae than levofloxacin, another third-generation 
fluoroquinolone.7 Preferably, gatifloxacin should not be 
used as a first-line drug. It should rather be reserved to treat 
cases that are unresponsive to more conventional drugs. 
It is registered for the treatment of bacterial conjunctivitis 
that is caused by staphylococci, streptococci, Haemophilus 
influenzae and Corynebacterium propinquum. It is also very 
effective in treating more severe cases of bacterial keratitis.2 
Moxifloxacin
Available preparation: 5 mg/ml drops
Moxifloxacin is another third-generation fluoroquinolone 
that covers the same spectrum as gatifloxacin, but 
demonstrates superior activity to S. pneumoniae.7 It is 
also effective against Acinetobacter spp., E. coli, Serratia 
marcescens and Chlamydia trachomatis. Despite only 
being licenced to treat bacterial conjunctivitis, moxifloxacin 
is often highly effective in treating moderate to severe 
bacterial keratitis. Therefore, ideally it should be reserved 
for more complicated cases to minimise the emergence of 
antibiotic resistance.
CPD Article: Anti-infective ophthalmic preparations in general practice
305
Doxycycline
Tetracycline eye ointment is indicated for the treatment of 
chlamydial inclusion conjunctivitis. Unfortunately, it is not 
available in South Africa.8 An alternative treatment option 
for this condition is an oral tetracycline, such as doxycycline 
100 mg twice daily for three weeks. Trachoma, another 
chlamydial infection, may also be treated with the same 
oral dose of doxycycline, but requires a longer treatment 
period of 3-6 weeks. Furthermore, oral doxycycline is used 
in the treatment of other eye conditions, such as posterior 
blepharitis and ocular rosacea, but the mechanism of action 
is not antibacterial in these conditions.
Azithromycin
Azithromycin provides a further treatment option for chla-
mydial inclusion conjunctivitis. In adults, a single dose of 
1 g is given orally, while a single dose of 20 mg/kg,1 or alter-
natively three daily doses of 10 mg/kg, may be administered 
to neonates.2 Chlamydial conjunctivitis is a sexually trans-
mitted infection in adults. Therefore, appropriate steps need 
to be taken to trace and treat all sexual partners.
Ceftriaxone
Ceftriaxone is a third-generation cephalosporin with 
excellent action against organisms such as H. influenzae, 
S. pneumoniae and N. gonorrhoeae.2 Therefore, it is used to 
treat gonococcal conjunctivitis in both adults and neonates. 
A single dose of 1 g should be given intramuscularly to 
adults, while a single dose of 125 mg should be given 
to neonates. If corneal involvement is present, a topical 
fluoroquinolone or tobramycin for use every hour should 
also be commenced before the patient is referred to an 
ophthalmologist.1 Once again, the sexual partners of 
infected adults should be traced and treated.
Co-amoxiclav
Co-amoxiclav is often used to treat soft tissue infections 
around the eye, since it not only provides good Gram-positive 
and Gram-negative cover, but also exhibits good efficacy 
against anaerobic organisms. Mild cases of dacryocystitis 
and preseptal cellulitis in patients who are otherwise well 
may safely be treated with co-amoxiclav in a family practice 
setting. Patients who are acutely ill, or those who may 
require surgical incision and drainage, should preferably be 
hospitalised and referred for an ophthalmology opinion.
Erythromycin
Erythromycin is a macrolide antibiotic that is effective against 
neonatal chlamydial conjunctivitis. The recommended 
oral dosage is 50 mg/kg/day in four divided doses for 
2-3 weeks. This should be combined with topical 
sulphacetamide to be applied two to three times a day for 
3-6 weeks, since neither erythromycin nor tetracycline are 
available in a topical preparation in South Africa.
Antiviral ophthalmic preparations
Aciclovir 
Aciclovir is a guanosine analogue that is effective against 
a variety of herpesviridae, including herpes simplex 1 and 
2, varicella-zoster virus and Epstein Barr virus. Aciclovir 
shows a high degree of selectivity for herpes-virus-infected 
cells, as a result of its unique mechanism of action. In short, 
phosphorylation of aciclovir to aciclovir monophosphate 
occurs more efficiently in virus-infected cells, because 
of the presence of viral thymidine kinase. The aciclovir 
monophosphate is then converted to a triphosphate form 
which inhibits viral DNA polymerase to a much greater 
extent than host cell DNA polymerase. Therefore, aciclovir 
has little effect on DNA synthesis in normal cells, but is a 
potent inhibitor of herpes-virus replication.9
Aciclovir 3% ointment is the drug of choice when treating 
herpetic conjunctivitis and dendritic corneal ulcers. It should 
be applied five times per day. Referral to an ophthalmologist 
may be necessary if a dendritic ulcer has not healed after 
seven days of treatment. If topical acyclovir is not available, 
oral acyclovir 400 mg five times per day may be used as 
an alternative since orally administered aciclovir reaches 
therapeutic levels in the precorneal tear film. Oral aciclovir 
is more effective than a topical application in treating 
vesicular eruptions of the periocular skin in primary herpetic 
blepharoconjunctivitis. In a general practice setting, oral 
aciclovir is the most important drug in the treatment of 
herpes zoster ophthalmicus. The recommended dosage in 
adults is 800 mg five times a day for 7-10 days, but this 
dosage should be reduced in patients with renal impairment.
Ganciclovir 
Ganciclovir is another guanosine analogue that is effective 
against all the herpesviridae, but is 10-25 times more active 
against cytomegalovirus (CMV) due to its specific chemical 
structure.9 Recently, a topical 0.15% preparation was 
launched in the USA to treat herpes keratitis. It was shown 
to be as effective as topical aciclovir for this indication and 
will hopefully be available in South Africa soon. Ganciclovir 
is also used by ophthalmologists to treat CMV retinitis in 
immunocompromised patients. It may be administered 
intravenously or by injection into the vitreous humour.
Famciclovir
Famciclovir is a prodrug of penciclovir and has a similar 
mechanism of action to aciclovir, in that it inhibits viral DNA 
polymerase. It is well absorbed orally and requires a lower 
dose and less frequent administration than aciclovir in the 
treatment of herpes zoster ophthalmicus. Unfortunately, 
it is considerably more expensive than aciclovir. The 
recommended dosage is 250 mg three times a day for 
seven days.
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Valaciclovir 
Valaciclovir is a prodrug of aciclovir which may also be used 
to treat herpes zoster ophthalmicus. The recommended oral 
dose is 1 g three times a day for seven days.
Trifluorothymidine 
Trifluorothymidine (TFT) is a thymidine analogue that 
inhibits the enzyme thymidine synthetase. Therefore, it has 
a different mechanism of action to acyclovir. This implies 
that TFT should be effective in cases of aciclovir-resistant 
herpetic keratitis. Unfortunately, it is no longer available in 
South Africa, despite still being widely used in the USA and 
Canada.
Antifungal ophthalmic preparations
Fungal keratitis is a sight-threatening condition that requires 
specialist management. A fungal aetiology should always 
be considered in any keratitis that results from an injury 
involving organic matter, especially if the injury leads to 
indolent ulceration. An interesting fact about fungal keratitis 
is that currently there is only one available commercial 
preparation for its treatment. The drug, natamycin, is 
derived from the bacterium, Streptomyces natalensis, 
which was first discovered in the former Natal province of 
South Africa and is now used worldwide as a first-choice 
agent in many cases of fungal keratitis. All other ophthalmic 
topical antifungal agents need to be specially prepared by a 
pharmacist and should be reserved for specialist use.
Antiparasitic ophthalmic preparations
Many parasites, both microscopic and macroscopic, 
may infect different parts of the eye. Examples include 
Acanthamoeba keratitis, Microsporidia keratitis, 
Pneumocystis jiroveci choroiditis and Toxoplasma gondii 
retinitis. Infestation by Onchocerca volvulus, a helminth, 
causes onchocerciasis or river blindness, which commonly 
occurs in neighbouring countries such as Zimbabwe. It is 
also sporadically seen in South Africa. Treatment comprises 
a single 150 μg/kg dose of oral ivermectin. The dose may be 
repeated after six months if the patient is still symptomatic. 
All of these infections require specialist management, 
although fairly simple drugs sometimes play an important 
role in their treatment. Propamidine isethionate is sometimes 
used to treat superficial bacterial ocular infections, but also 
plays an important role in the treatment of Acanthamoeba 
keratitis, in combination with other agents such as 0.02% 
chlorhexidine gluconate solution.
Miscellaneous ophthalmic preparations
Povidone iodine
Povidone iodine 5%, an organic iodine antiseptic agent, 
is widely used in the preoperative cleansing of the 
periocular skin and ocular surface. It has brought about 
a dramatic reduction in the incidence of postoperative 
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endophthalmitis.10 It has been shown that a 2.5% solution 
used on the conjunctivae of newborns was more effective 
than both silver nitrate and erythromycin in preventing 
ophthalmia neonatorum,11 but not quite as effective as 1% 
tetracycline ointment.12 However, the latter is not available 
in South Africa. Povidone iodine 2% possesses antiv iral 
properties and has proved to be effective in relieving the 
symptoms of 77% of patients who were treated for epidemic 
keratoconjunctivitis (“pink eye”) within a week.13 Therefore, 
povidone iodine is an important anti-infective ophthalmic 
preparation. It plays both a prophylactic and a therapeutic 
role.
Antibiotic-steroid combinations
Many of the topical antibacterial agents are also available in 
combination with a topical corticosteroid. Examples include 
Tobradex® (tobramycin plus dexamethasone), Spersadex 
Comp® (chloramphenicol plus dexamethasone) and 
Betnesol N® (betamethasone plus neomycin). These drugs 
are predominantly used before and after eye operations to 
decrease inflammation and prevent infection in the operated 
eye. Their use is not recommended in the treatment of 
blepharitis, conjunctivitis or keratitis of unknown origin 
since the corticosteroid component will exacerbate any 
undiagnosed herpetic infection. Therefore, the use of 
combination therapy is not encouraged in general practice.2 
Conclusion
The number of topical anti-infective ophthalmic 
preparations that are available commercially is relatively 
small. The majority of these agents are intended for use 
against bacterial infections which are relatively easy to 
diagnose and treat. First-line drugs, such as tobramycin, 
chloramphenicol, ciprofloxacin and ofloxacin, are currently 
still very effective in curing most superficial bacterial 
ocular infections. The third-generation fluoroquinolones, 
gatifloxacin and moxifloxacin, should preferably be 
reserved for cases that do not respond to first-line agents 
to minimise the development of resistance to these drugs. 
Oral antibacterial drugs may also be required to prevent and 
treat certain ophthalmic conditions.
Far fewer commercial options exist for the treatment of 
viral, fungal and parasitic infections. Both topical and oral 
aciclovir play an important role in the treatment of ocular 
herpetic infections. To prevent iatrogenic exacerbation, 
these infections need to be actively excluded before 
considering the use of a topical preparation that contains a 
corticosteroid. Fungal and parasitic infections often mimic 
bacterial infections and are then only diagnosed when they 
do not respond to antibacterial therapy. These conditions 
are notoriously difficult to treat and should rather be referred 
for specialist management.
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